Tivic Health Systems

Tivic Health Systems ROE

The Return on Equity (ROE) of Tivic Health Systems (TIVC) as of Nov 2, 2026 is -52.85 %. In the previous year, Return on Equity (ROE) was -223.08 % — a change of -76.31% (higher).

ROE

-52.85 %

YoY

-76.31%

Last updated:

In 2025, Tivic Health Systems's return on equity (ROE) was -52.85 %, a -76.31% increase from the -223.08 % ROE in the previous year.

The Tivic Health Systems ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
-174.95 USD
Jan 1, 2020
309.18 USD
Jan 1, 2021
-64.00 USD
Jan 1, 2022
-278.13 USD
Jan 1, 2023
-230.28 USD
Jan 1, 2024
-223.08 USD
Jan 1, 2025
-52.85 USD
The Tivic Health Systems ROE history
YEARROEYoY
-52.85 %-76.31%
-223.08 %-3.13%
-230.28 %-17.20%
-278.13 %+334.58%
-64.00 %-120.70%
309.18 %-276.73%
-174.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tivic Health Systems Stock analysis

What does Tivic Health Systems do? Tivic Health Systems Inc is a commercial-stage health tech company advancing bioelectronic medicine with patented technology that stimulates trigeminal, sympathetic, and vagus nerve structures. Its first commercial product, ClearUP, is an FDA-approved handheld bioelectronic sinus device clinically proven and doctor-recommended for treating inflammatory chronic conditions. ClearUP is sold directly to consumers in the U.S. through online retailers and commercial distributors, with reseller channels expanding its market reach. The company focuses on expanding its intellectual property portfolio and research programs related to vagus nerve stimulation for broader therapeutic applications. ClearUP serves consumers seeking drug-free therapeutic solutions for sinus conditions, targeting individuals with inflammatory chronic health issues who prefer non-invasive treatments. Healthcare providers recommend ClearUP as a safe, low-risk alternative to medication, appealing to patients looking for high safety profiles in treatment options. The company's revenue streams derive from direct consumer sales and reseller partnerships, leveraging its FDA approval and clinical validation to drive market adoption. Tivic Health Systems develops its products around non-invasive nerve stimulation technology, with ClearUP being the primary revenue-generating product. The company's strategy centers on expanding its IP portfolio to support future product development in bioelectronic medicine, particularly in vagus nerve stimulation applications. By focusing on clinical validation and doctor recommendations, Tivic Health aims to position itself as a leader in drug-free therapeutic solutions for chronic inflammatory conditions. Tivic Health Systems is one of the most popular companies on Eulerpool.

ROE Details

Decoding Tivic Health Systems's Return on Equity (ROE)

Tivic Health Systems's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Tivic Health Systems's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Tivic Health Systems's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Tivic Health Systems’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Tivic Health Systems stock

Return on Equity (ROE) of Tivic Health Systems is -52.85 % in 2025.

Return on Equity (ROE) of Tivic Health Systems changed from -223.08 % to -52.85 %, representing a -76.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Tivic Health Systems since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Tivic Health Systems with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Tivic Health Systems

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Tivic Health Systems